Investigational Anti SARS-COVID 19 Medication

The newly identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV- 2) that originated in December 2019 in Wuhan, China. By July 2020, the WHO reported over 17 million confirmed cases in over 200 countries around the globe. This review discusses how the COVID-19 pandemic may affect healthy people, structure and replication cycle of SARS- CoV-2; targets and therapeutics SARS- CoV-2 and anti-COVID drugs: strategies and perspectives

Pharmacogenetics- gene and SARS-COVID 19 Medication

An analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes collected from the patients worldwide has identified mutations in the virus that could aid in drug and vaccine development. The researchers found that the virus’s genetic diversity in most countries is similar to what it is globally, suggesting that it was introduced repeatedly by many infected people in each country rather than by a “patient zero.” The genetic analysis found 198 mutations that have occurred more than once. “Mutations in themselves are not a bad thing it is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected. Several factors, including pharmacogenetics, it is possible to contribute to inter-individual variability in drug response. However, till today little is known about the host genetics interaction with infection and COVID-19 progression. To understand the role of host gene, we review the current literature, aggregate readily available genetic resources, and provide some updated analysis relevant to COVID-19 and associated phenotypes